CompletedNCT00206141

Safety study of efficacy & Safety of Quetiapine Fumarate & Lithium in depression in bipolarity

This study is completed in Canada, in Croatia, in Estonia, .... It is testing efficacy & Safety of Quetiapine Fumarate & Lithium for depression in bipolarity.

Bipolarity, DepressionDrugFrom 18 Years to 65 Years

The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.

Explore recruiting studies on this topic

Then choose your country and confirm availability with each study site.

In plain English

Key information made simple

This summary needs review. Please check the official study record and contact the research team for details.

Your next step

Check the study details

Check the official source, then confirm these points with the research team.

View official study record

Recruitment and eligibility
Is a site open, and who can take part?
Visits and time
Where are visits, can any be remote, and how much time is needed?
Costs and support
What costs, reimbursement or compensation apply?

Before joining

Questions to ask before joining

What are the exact eligibility criteria, and what could exclude someone?
How many visits, assessments, or follow-ups are expected, and over what period?
What risks, side effects, practical burdens, or alternatives should be understood first?
Who should be contacted to confirm locations, timing, compensation, and next steps?

Study clarity

Things to check before joining

Study start dateAugust 2005

Recruitment status: Completed
Enrollment listed in the registry: 672
Sponsor: AstraZeneca
Sponsor type: Unknown or unclear
Study type: Drug
Intervention type: Medication / drug
Study phase: Phase 3
Locations: Canada, Croatia, Estonia, ...
Age range: From 18 Years to 65 Years
Official registry ID: NCT00206141
Official title: Multi-centre, Double-blind, Randomised, Parallel-group, Placebo-controlled, Phase 3 Study of the Efficacy & Safety of Quetiapine Fumarate & Lithium as Monotherapy in Adult Patients With Bipolar Depression for 8 Weeks & Quetiapine in Continuation (Abbreviated)

Ask HopeStage to help me review this study

This record does not confirm open recruitment. We can help you understand it and explore other studies.

Study ID: NCT00206141. We help you review the study, but cannot decide medical eligibility.

Check recruitment and locations

Recruitment checked against the registry by HopeStage on 15 September 2026. Registry information can change. Always confirm availability with the research team.

View official study record

The overall study status can differ from each site's status. Open a country to see its locations and their registry status.

Canada · 9 sites

Research Site
Kelowna, British Columbia
Site status: Not listed — confirm with the team
Research Site
Sydney, Nova Scotia
Site status: Not listed — confirm with the team
Research Site
Greater Sudbury, Ontario
Site status: Not listed — confirm with the team
Research Site
Markham, Ontario
Site status: Not listed — confirm with the team
Research Site
Mississauga, Ontario
Site status: Not listed — confirm with the team
Research Site
Orléans, Ontario
Site status: Not listed — confirm with the team
Research Site
Waterloo, Ontario
Site status: Not listed — confirm with the team
Research Site
Montreal, Quebec
Site status: Not listed — confirm with the team
Research Site
Sherbrooke, Quebec
Site status: Not listed — confirm with the team

Croatia · 4 sites

Research Site
Osijek
Site status: Not listed — confirm with the team
Research Site
Split
Site status: Not listed — confirm with the team
Research Site
Zadar
Site status: Not listed — confirm with the team
Research Site
Zagreb-Susedgrad
Site status: Not listed — confirm with the team

Estonia · 3 sites

Research Site
Kohtla-Järve
Site status: Not listed — confirm with the team
Research Site
Tallinn
Site status: Not listed — confirm with the team
Research Site
Tartu
Site status: Not listed — confirm with the team

Germany · 2 sites

Research Site
Berlin
Site status: Not listed — confirm with the team
Research Site
Würzburg
Site status: Not listed — confirm with the team

Indonesia · 3 sites

Research Site
Solo, Java
Site status: Not listed — confirm with the team
Research Site
Jakarta
Site status: Not listed — confirm with the team
Research Site
Lawang
Site status: Not listed — confirm with the team

Latvia · 2 sites

Research Site
Daugavpils
Site status: Not listed — confirm with the team
Research Site
Riga
Site status: Not listed — confirm with the team

Lithuania · 3 sites

Research Site
Kaunas
Site status: Not listed — confirm with the team
Research Site
Šiauliai
Site status: Not listed — confirm with the team
Research Site
Vilnius
Site status: Not listed — confirm with the team

Malaysia · 3 sites

Research Site
Kuala Lumpur
Site status: Not listed — confirm with the team
Research Site
Kuching Sarawak
Site status: Not listed — confirm with the team
Research Site
Petaling Jaya
Site status: Not listed — confirm with the team

Norway · 5 sites

Research Site
Brattvåg
Site status: Not listed — confirm with the team
Research Site
Drammen
Site status: Not listed — confirm with the team
Research Site
Fredrikstad
Site status: Not listed — confirm with the team
Research Site
Mysen
Site status: Not listed — confirm with the team
Research Site
Paradis
Site status: Not listed — confirm with the team

Philippines · 4 sites

Research Site
Davao City
Site status: Not listed — confirm with the team
Research Site
Iloilo City
Site status: Not listed — confirm with the team
Research Site
Mandaluyong
Site status: Not listed — confirm with the team
Research Site
Manila
Site status: Not listed — confirm with the team

Poland · 8 sites

Research Site
Bialystok
Site status: Not listed — confirm with the team
Research Site
Bydgoszcz
Site status: Not listed — confirm with the team
Research Site
Gdynia
Site status: Not listed — confirm with the team
Research Site
Leszno
Site status: Not listed — confirm with the team
Research Site
Lodz
Site status: Not listed — confirm with the team
Research Site
Skorzewo
Site status: Not listed — confirm with the team
Research Site
Wroclaw
Site status: Not listed — confirm with the team
Research Site
Zabrze
Site status: Not listed — confirm with the team

Russia · 12 sites

Research Site
Arkhangelsk
Site status: Not listed — confirm with the team
Research Site
Kazan'
Site status: Not listed — confirm with the team
Research Site
Lipetsk
Site status: Not listed — confirm with the team
Research Site
Moscow
Site status: Not listed — confirm with the team
Research Site
Nizhny Novgorod
Site status: Not listed — confirm with the team
Research Site
Rostov-on-Don
Site status: Not listed — confirm with the team
Research Site
Saint Petersburg
Site status: Not listed — confirm with the team
Research Site
Saratov
Site status: Not listed — confirm with the team
Research Site
Smolensk
Site status: Not listed — confirm with the team
Research Site
Stavropol
Site status: Not listed — confirm with the team
Research Site
Tver'
Site status: Not listed — confirm with the team
Research Site
Yaroslavl
Site status: Not listed — confirm with the team

Serbia · 5 sites

Research Site
Belgrade
Site status: Not listed — confirm with the team
Research Site
Čačak
Site status: Not listed — confirm with the team
Research Site
Kragujevac
Site status: Not listed — confirm with the team
Research Site
Niš
Site status: Not listed — confirm with the team
Research Site
Valjevo
Site status: Not listed — confirm with the team

South Korea · 2 sites

Research Site
Gyeonggi-do
Site status: Not listed — confirm with the team
Research Site
Seoul
Site status: Not listed — confirm with the team

Taiwan · 2 sites

Research Site
Changhua
Site status: Not listed — confirm with the team
Research Site
Taipei
Site status: Not listed — confirm with the team

Ukraine · 9 sites

Research Site
Dnipropetrovsk
Site status: Not listed — confirm with the team
Research Site
Donetsk
Site status: Not listed — confirm with the team
Research Site
Kharkiv
Site status: Not listed — confirm with the team
Research Site
Kiev
Site status: Not listed — confirm with the team
Research Site
Luhansk
Site status: Not listed — confirm with the team
Research Site
Lviv
Site status: Not listed — confirm with the team
Research Site
Odesa
Site status: Not listed — confirm with the team
Research Site
Simferopol
Site status: Not listed — confirm with the team
Research Site
Vinnitsa
Site status: Not listed — confirm with the team

In practice

For you

Participation may contribute to research. Personal benefit is not guaranteed.

Ask the research team to explain the activities, time commitment, and follow-up involved.

Study sites are listed. Confirm the relevant site and any travel before making plans.

Important

Not medical advice

Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com

FAQ

Questions about this study

What is this study trying to understand?

This study is exploring medication or study treatment for people with bipolarity. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed. The detailed objective is not always clearly listed in the public registry; the study team can confirm.

Does this study involve a medication?

This appears to be a medication / drug study involving Quetiapine Fumarate (Seroquel™) drug, mood stabilizer (mood). Phase 3 studies are usually larger and aim to confirm effectiveness and safety in a broader group.

Who might this study be for?

This study may concern people with bipolarity; age range: From 18 Years to 65 Years. The criteria appear fairly broad, but you should not assume you are eligible. The study team must confirm diagnosis, age, exclusions, available locations, and next steps.

What would I likely need to do?

You may need to take a study treatment and have regular medical follow-up. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.

What side effects, interactions, or treatment changes should I check?

If the study involves a medication, ask whether it is already approved, experimental, or being tested for a new use. Check possible side effects, interactions with current treatment, dose changes, monitoring, and what happens if you feel worse. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.

Will I need to travel or attend in-person visits?

The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.

Who is behind this study?

This study is sponsored by AstraZeneca, which appears to be unknown or unclear. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.

Can I still join this study?

The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.

Explore other studies

Want to find a study that may fit you better?

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.

Find a study that may fit me

Safety study of efficacy & Safety of Quetiapine Fumarate & Lithium in depression in bipolarity

Key information made simple

Check the study details

Recruitment and eligibility

Visits and time

Costs and support